TX-FLUENCE
11.8.2022 14:32:09 CEST | Business Wire | Press release
Fluence Bioengineering, Inc. (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, in collaboration with REMY, a horticultural lighting provider to Israel’s growing agriculture industry, is supporting the record introduction of lighting technology solutions to Israel’s medical cannabis facilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005211/en/
Israel—considered a world leader in cannabis research, cultivation and advanced regulation—has positioned itself at the forefront of the $74 trillion global cannabis market through highly innovative technology and data applications. The country now boasts supply capabilities that surpass its domestic demand. As the Israeli market matures, more and more indoor farms are capitalizing on leading controlled environment agriculture strategies proven to optimize plant growth and profits.
REMY’s expertise, paired with Fluence’s products and evidence-based best practices for optimal lighting strategies at each phase of cannabis growth, has placed the companies’ collaborative designs in the three core categories of medical cannabis facilities in Israel: greenhouse, indoor and vertical farms.
Hybrid cultivation at Green Fields
Green Fields, which operates the largest medical cannabis growing facility in Israel, features a hybrid greenhouse model of harnessing sunlight and supplementing with artificial lighting to optimize plant quality. The forward-looking company chose Fluence and REMY to install a high-intensity lighting system.
"After working on several projects with REMY, we know the value of their professionalism, expertise and service. That's why we chose them for our flagship project," explained Jonathan Pisso, chief procurement officer of Green Fields. "The difference we saw in the first crop cycle using Fluence lighting was phenomenal. As a result of the facility's control system, we have a great deal of flexibility and maximum control. We have integrated all the technologies with an extremely powerful lighting system, which results in uniform growth and excellent results."
Growing indoors with Springs Valley Cannabis
Another popular type of cannabis facility in Israel is the fully indoor model, which allows control of all crop conditions to ensure uniform growth throughout the year while maximizing quality. Springs Valley Cannabis is setting up to become a major cannabis cultivator in Israel. It elected to use Fluence and REMY for lighting solutions in its indoor facility that covers an impressive 5,000 square meters of canopy.
"When we designed our unique facility, we sought trustworthy partners who would ensure our product would be a market leader. We found it in the combination of Fluence and REMY," said Yossi Shitrit, founder of Springs Valley Cannabis.
Trichome’s urban vertical farm
Located in the heart of an urban industrial area, Trichome operates a fully indoor, multi-tier vertical farming facility. Harnessing the power and control of indoor cultivation methods, Trichome searched for industry-leading partners with experience optimizing environmental parameters in a multi-tier environment. With Fluence’s SPYDR Series, Trichome leverages a high intensity, broad-spectrum strategy that delivers precise and uniform light to the plant canopy.
"Fluence’s and REMY's teams are extremely professional. They are dedicated to our success and bring us added value. The results are already exceeding our initial expectations," said Tony Levi, founder and CEO at Trichome. "It shows the potential for indoor growth in urban centers. The facility utilizes every square meter of the building for efficiency and uniformity."
"Israel is a technological 'playground' for the cannabis market, which makes it easy to examine and adopt advanced technologies quickly," said Timo Bongartz, general manager for Europe, the Middle East and Africa (EMEA) at Fluence. "With the early-adapter frame of mind that the Israeli industry practices, Fluence has managed to deliver expert horticulture knowledge and, together with REMY, cooperate with leading innovative growers to advance their operations."
In addition to providing lighting solutions, REMY specializes in the planning, installation, integration and quality assurance of large-scale agronomic solutions, as well as after-sales service and support.
"At the end of the day, the plant is the best indication for our success or failure—and we are achieving success in multiple, diverse cultivation environments," said Elad Toby, founder, CTO and chief business development officer for REMY.
To learn more about REMY, click here . To learn more about Fluence’s portfolio of luminaires and lighting controls, visit the company’s website here .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About REMY
Established in 2008, REMY 108 LTD specializes in the planning, installation, integration and quality assurance of large-scale agronomic lighting solutions, as well as after-sales service and support, for commercial crop and food cultivation in Israel and beyond. REMY has been providing its customers with agronomic lighting since 2011 and it has been the company’s main focus since 2018. An authorized reseller of Fluence LED lighting solutions, it today also provides agronomic lighting training at its headquarters in Yanuv. For more information about REMY, visit https://www.remy.co.il/en/grow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom